Articles tagged "Heart transplant patients"

2015 American Transplant Congress
A New Diagnostic Tool for Antibody Mediated Rejection in Heart and Lung Transplantation: Intragraft Donor Specific Anti-HLA Antibodies Detection
J. Olagne,^1,2,3 A. Parissiadis,² N. Froelich,² S. Caillard,¹ M.-P. Chenard,³ E. Epailly,⁴ H. Kremer,⁴ T. Degot,⁵ S. Hirschi,⁵ R. Kessler,⁵ B. Moulin.¹
¹Service de Néphrologie - Transplantation, Centre Hospitalier Universitaire, Strasbourg, France; ²Laboratoire d'Histocompatibilité, Etablissement Français du Sang, Strasbourg, Alsace, France; ³Département de Pathologie, Centre Hospitalier Universitaire, Strasbourg, France; ⁴Service de Cardiologie, Centre Hospitalier Universitaire, Strasbourg, France; ⁵Service de Pneumologie, Centre Hospitalier Universitaire, Strasbourg, France.
INTRODUCTION: Antibody mediated rejection (AMR) is one of the causes of dysfunction and graft loss. The limited histological features, with a weak sensibility of c4d,…
2015 American Transplant Congress
Prevalence, Risk Factors, and Clinical Management of Chronic Renal Dysfunction in Heart Transplant Recipients
K. Xhima, O. Famure, Y. Li, J. Kim.
Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Background: Chronic kidney disease (CKD) is a frequent complication after heart transplantation. The magnitude of post-transplant CKD makes it necessary to characterize patients at increased…
2015 American Transplant Congress
Long-Term Results After Heart Transplantation – A Randomized Trial Comparing Tacrolimus Versus Cyclosporine A in Combination With Mycophenolate Mofetil After a Mean Duration of 15 Years
S. Guethoff,¹ C. Grinninger,¹ B. Reichart,² P. Ueberfuhr,¹ C. Hagl,¹ B. Meiser.²
¹Department of Cardiac Surgery, Ludwig-Maximilians University, Munich, Germany; ²Transplantation Center, Ludwig-Maximilians University, Munich, Germany.
Purpose. Development of cardiac allograft vasculopathy (CAV), renal dysfunction and malignancies are the main risks due to long-term immunosuppressive therapy after heart transplantation (HTx). We…
2015 American Transplant Congress
Tracking T Cell Fate After Antithymocyte Globulin (ATG) Immunotherapy in Infant Heart Transplant (HTx) Patients
S.-I. Wang,^1,2 I. Larsen,^1,2 S. Urschel,^1,2 R. Chinnock,³ J. Rusch,³ L. West.^1,2
¹Univ. of Alberta, Edmonton, Canada; ²Alberta Transplant Institute, Edmonton, Canada; ³Loma Linda Univ., Loma Linda.
Polyclonal T cell depletion with ATG is a common induction therapy in adult and pediatric transplantation. In adults, T cell recovery post-ATG involves homeostatic proliferation…
2015 American Transplant Congress
Evaluation of Medication Regimen Complexity Over Time Following Heart Re-Transplantation
B. Bryant,¹ A. Libby,¹ R. Page,¹ J. Lindenfeld,² C. Aquilante.¹
¹University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO; ²University of Colorado School of Medicine, Aurora, CO.
Medication regimen complexity (MRC) includes many characteristics of a drug regimen. Previously, we showed that MRC is high and persists over time after primary heart…
2015 American Transplant Congress
The Correlation Between Donor Specific Antibodies and Heart Transplant Rejection
R. Bedard,¹ P. Jindra,² M. Manson,¹ M. Moaddab,¹ H. Mallidi,³ W. Etheridge,¹ A. Civitello,³ R. Kerman.²
¹CHI St. Luke's Health - Baylor St. Luke's Medical Center, Houston, TX; ²Immune Evaluation Laboratory, Baylor College of Medicine, Houston, TX; ³Texas Heart Institute, Baylor College of Medicine, Houston, TX.
The presence of donor specific HLA antibodies (DSA) has been shown to be detrimental to heart transplant (HTx) survival. Virtual crossmatching (VXM) offers a rapid…
2015 American Transplant Congress
Plasma Levels of Donor-Derived Cell-Free DNA Increase With Rejection and Often Decrease After Treatment in Organ Transplant Recipients
M. Grskovic,¹ J. Beausang,¹ D. Hiller,¹ R. Sit,¹ B. Christie,¹ J. Elechko,¹ R. Woodward,¹ J. Yee,¹ J. Kobashigawa.²
¹CareDx, Inc, Brisbane, CA; ²Cedars-Sinai Medical Center, Los Angeles, CA.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a potential biomarker of acute cellular rejection (ACR) in organ transplant recipients. dd-cfDNA levels in longitudinal plasma samples from…
2015 American Transplant Congress
C1q Reactivity and IgG Subtypes After HLA Antibody Removal Therapy With Carfilzomib in Thoracic Transplant Recipients
A. Zeevi, M. Marrari, C. Bentlejewski, J. Pilewski, M. Morrell, J. McDyer, M. Shullo, J. Teuteberg, C. Bermudez, C. Ensor.
Univ of Pittsburgh, Pittsburgh.
Conventional therapies for antibody removal consisting of plasma exchange with IVIG and Rituximab are partially effective in desensitization protocols and for treatment of antibody mediated…
2015 American Transplant Congress
Effects of Anti-Human Leukocyte Antigen Antibody After Heart Transplantation
F. Liou, M. Kittleson, J. Patel, S. Siddiqui, M. Luu, B. Kearney, D. Ramzy, D. Chang, L. Czer, N. Reinsmoen, J. Kobashigawa.
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: The development of donor-specific antibodies (DSA) after heart transplant has been correlated to the subsequent development of graft rejection. The development of DSA are…
2015 American Transplant Congress
Elevated ST2 Levels Are Associated With Increased Risk of Antibody Mediated Rejection in Heart Transplant Recipients
A. Grupper,¹ S. Kushwaha,¹ O. Abou Ezzeddine,¹ J. Geske,² W. Kremers,² B. Edwards,¹ N. Pereira.¹
¹Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; ²Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
Objective: Serum ST2, a member of the interleukin (IL) 1 receptor family, is a novel biomarker that reflects cardiac remodeling and fibrosis and is associated…